Oppenheimer lowers Acadia Pharmaceuticals price target on pipeline outlook
Oppenheimer has reduced its price target for Acadia Pharmaceuticals (NASDAQ:ACAD) to $21 from $23, maintaining a Perform rating, citing commercial outlook and pipeline opportunities. Despite a missed primary endpoint in Phase 2 for remlifanserin, CTAD analyses support Phase 3 advancement. The company's Daybue STIX and ex-US expansion, including a new Japan partnership, are noted as key growth drivers, while upcoming Phase 2 data for ACP-211 in MDD and potential business development are also highlighted.
ACADIA Pharmaceuticals Eyes Deals as DAYBUE Growth Fuels Revenue Surge
ACADIA Pharmaceuticals is actively pursuing growth for its DAYBUE and NUPLAZID franchises, while also advancing neurological and psychiatric drug candidates and seeking external deals. The company reported a 22% increase in quarterly revenue to $342 million, driven by strong DAYBUE and NUPLAZID sales, and raised its annual DAYBUE revenue guidance. With over $970 million on its balance sheet, ACADIA plans to invest in its pipeline and strategic business development, alongside expanding its market reach for DAYBUE, launching it internationally, and addressing patent appeals and pipeline updates for other drug candidates.
Acadia Pharmaceuticals Presents Additional Phase 2 RADIANT Study Results Evaluating Remlifanserin for the Treatment of Alzheimer's Disease Psychosis at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Acadia Pharmaceuticals presented additional Phase 2 RADIANT study results for remlifanserin in Alzheimer's disease psychosis, showing the 60 mg dose outperformed placebo on several secondary measures despite narrowly missing the primary endpoint. The company expressed continued confidence in the drug's activity as it proceeds with Phase 3 development. Safety and tolerability were consistent with previous results.
Acadia Pharma to commercialise DAYBUE® STIX (trofinetide) in Japan for treatment of Rett syndrome
Acadia Pharmaceuticals has signed an exclusive distribution agreement with KYORIN Pharmaceutical to commercialise DAYBUE® STIX (trofinetide) in Japan for treating Rett syndrome. Acadia will receive an upfront payment of $30 million, potential future regulatory and sales milestones, and a share of net sales. This follows Acadia's completed Phase 3 study in Japan, which showed results consistent with its pivotal LAVENDER™ Phase 3 study.
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
Acadia Pharmaceuticals has signed an exclusive distribution agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan, aimed at treating Rett syndrome. Under the agreement, KYORIN will manage commercialization and regulatory activities, while Acadia will receive an upfront payment of $30 million, potential future milestone payments, and a share of net sales. This partnership follows positive Phase 3 study results in Japan, consistent with previous pivotal studies, and expands global access to DAYBUE.
Why ACADIA Pharmaceuticals stock is trading up today
ACADIA Pharmaceuticals' shares rose after announcing an exclusive distribution agreement with KYORIN Pharmaceutical Co., Ltd. for DAYBUE STIX in Japan for Rett syndrome. The deal includes an upfront payment of $30 million, potential future milestone payments, and a share of net sales. This agreement is seen by investors as a positive step for capital security and commercial expansion for DAYBUE STIX.
Acadia Pharmaceuticals strikes Japan deal with Kyorin for Rett drug
Acadia Pharmaceuticals has signed an exclusive distribution agreement with KYORIN Pharmaceutical to commercialize DAYBUE STIX (trofinetide) in Japan for Rett syndrome. Acadia will receive an upfront payment of $30 million, with potential for future regulatory and sales milestones, plus a share of net sales. The drug, already approved in the U.S., Canada, and the EU, recently completed a successful Phase 3 study in Japan.
Acadia Pharmaceuticals Enters Exclusive Distribution Agreement with KYORIN Pharmaceutical for DAYBUE® STIX (trofinetide) in Japan
Acadia Pharmaceuticals has signed an exclusive distribution agreement with KYORIN Pharmaceutical for the commercialization of DAYBUE STIX for Rett syndrome in Japan. Acadia will receive an upfront payment of $30 million, with additional eligibility for future regulatory and sales milestone payments, plus a share of Japanese net sales. This deal allows Acadia to enter the Japanese market without establishing its own sales infrastructure, leveraging KYORIN's expertise in the region.
Key facts: Morgan Stanley Cuts ACADIA Price Target; Analysts Retain Buy Consensus
Morgan Stanley has lowered its price target for ACADIA Pharmaceuticals Inc. (ACAD) to $24 from $28, while maintaining an Equal-Weight rating. Despite this, the average 12-month price target for ACADIA Pharmaceuticals Inc. (ACAD) among analysts stands at $30.11, indicating a potential 66% upside from its November 12 closing price. The consensus among analysts remains a "Buy," with 15 buy ratings, four holds, and one sell.
Morgan Stanley maintains Acadia Pharmaceuticals at Equal-Weight, lowers price target to $24 from $28
Morgan Stanley has maintained its "Equal-Weight" rating on Acadia Pharmaceuticals (ACAD) but reduced its price target to $24 from $28, representing a 14.3% decrease. This new target implies a 32.3% upside from the stock's closing price of $18.14 on November 12. Other recent analyst actions on Acadia Pharmaceuticals show price targets ranging from $35 to $38 from firms like Canaccord Genuity, RBC Capital, and Needham.
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $30.11, Implies 66% Upside
The average 12-month price target for ACADIA Pharmaceuticals Inc. stock has been reduced from $30.53 to $30.11 by 18 analysts, with a range of $16 to $38 per share. This updated target suggests a potential upside of approximately 66% based on the November 12 closing price. The consensus rating from 20 analysts remains "Buy," comprising 15 Buys, 4 Holds, and 1 Sell.
Acadia Pharmaceuticals (ACAD), What Is Behind The Latest Attention?
Acadia Pharmaceuticals (ACAD) is gaining attention due to strong Q3 revenue, increased full-year guidance, and ongoing patent appeals for Nuplazid. Despite positive developments, the share price has declined significantly over the past year, reflecting investor concerns about profitability and legal uncertainties. Analysts, however, see the company as undervalued, with a fair value of $30.53 compared to its current price of $18.37, contingent on successful execution of DAYBUE expansion and remlifanserin development.
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for ACADIA Pharmaceuticals Inc. (ACAD) stock, showing its current price of $18.00 with a 9.09% increase. It includes sections for analyst ratings, though no current data is available, and mentions earnings information is not present. The page also features a promotional section for Timothy Sykes and disclaimers about the risks of day trading.
One holder reports 7.65 million Acadia Pharmaceuticals (ACAD) shares.
State Street Corporation has reported beneficial ownership of 7,650,889 shares of Acadia Pharmaceuticals (ACAD) common stock, which represents 4.4% of the class, as of September 30, 2026. The filing indicates shared voting power over 7,263,092 shares and shared dispositive power over all 7,650,889 shares. Five State Street subsidiaries are identified in connection with this ownership position.
Why Is Acadia Pharmaceuticals (ACAD) Presenting New Remlifanserin Data Worth Watching?
Acadia Pharmaceuticals (ACAD) is set to present new clinical data for remlifanserin at the 2026 CTAD Conference, focusing on Alzheimer's disease psychosis. This presentation is crucial as it will provide updated findings for a late-stage asset that management positions as a key future revenue contributor, alongside DAYBUE and NUPLAZID. The data could clarify remlifanserin's potential in the large Alzheimer's psychosis market, especially after a prior Phase 2 miss, and influence investor perception of Acadia's pipeline opportunity.
Acadia Pharmaceuticals Comments on Federal Circuit Oral Argument in NUPLAZID® Formulation Patent Appeal
Acadia Pharmaceuticals announced that the Federal Circuit heard oral arguments regarding its appeal of a May 2025 Delaware ruling on the '721 patent for NUPLAZID 34 mg capsule formulation. The company anticipates a decision in the first half of 2027, which will determine whether formulation protection extends until February 2038 or shortens to October 2030 if the appeal is unsuccessful. NUPLAZID is also expected to be subject to negotiated Medicare pricing starting in 2029 under the Inflation Reduction Act.
Acadia Pharmaceuticals to Present Remlifanserin Data at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) Conference
Acadia Pharmaceuticals (ACAD) announced it will present data on remlifanserin and Alzheimer's disease psychosis (ADP) at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston, November 16-19, 2026. The presentations will include findings from the Phase 2 RADIANT clinical trial program and research on biomarker heterogeneity in ADP patients. Remlifanserin is a novel 5-HT2A receptor inverse agonist being developed for ADP and Lewy body dementia psychosis, addressing a condition with no current FDA-approved treatment.
Acadia Pharmaceuticals stock hits 52-week low at 18.24 USD
Acadia Pharmaceuticals Inc. (ACAD) shares recently hit a 52-week low of $17.86, down over 20% year-to-date, despite appearing undervalued with a P/E ratio of 9.98 and a PEG ratio of 0.28. The company recently surpassed Q3 2026 financial expectations, driven by strong sales of DAYBUE and NUPLAZID, leading RBC Capital to raise its price target to $38. Market observers are closely monitoring Acadia's strategic developments amidst its stock decline.
Acadia Pharmaceuticals stock hits 52-week low at 18.24 USD By Investing.com
Acadia Pharmaceuticals' stock recently hit a 52-week low, trading at $17.86, reflecting a more than 20% year-to-date decline. Despite this, the stock shows potential value with a P/E ratio of 9.98 and a low PEG ratio of 0.28, and InvestingPro analysis suggests it is undervalued. The company recently reported strong Q3 2026 financial results, surpassing Wall Street expectations with record sales for DAYBUE and NUPLAZID, leading RBC Capital to raise its price target to $38.
Acadia Pharmaceuticals Inc. Just Recorded A 58% EPS Beat: Here's What Analysts Are Forecasting Next
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) reported strong Q3 results, beating revenue estimates by 2.7% with US$342m and statutory EPS by 58% at US$0.31. Analysts are now forecasting revenues of US$1.45b in 2027, a 20% increase, and an EPS of US$0.96. Despite the upgraded EPS estimates, the consensus price target remains at US$30.68, suggesting no significant long-term positive impact on valuation.
Acadia Pharmaceuticals Inc. (ACAD) Seasonal Returns Chart - Yahoo Finance
The article provides a seasonal returns chart for Acadia Pharmaceuticals Inc. (ACAD) on Yahoo Finance. It displays the average monthly price return for the company between 2016 and 2026. The content also includes real-time stock price information and various financial data sections like news, charts, community, and statistics.
How Investors Are Reacting To Acadia Pharmaceuticals (ACAD) Raised Revenue Guidance
Acadia Pharmaceuticals reported strong Q3 2026 revenue of US$342.29 million and net income of US$53.52 million, leading to an increased full-year revenue guidance of US$1.265b to US$1.295b due to better-than-expected performance from DAYBUE and NUPLAZID. While revenue guidance was raised, net income and EPS were below last year, highlighting the need for cost discipline. Investors are also closely watching the progress of remlifanserin in dementia-related psychosis as a key long-term catalyst.
RBC raises Acadia Pharmaceuticals stock price target on Daybue growth By Investing.com
RBC Capital has increased its price target for Acadia Pharmaceuticals (NASDAQ:ACAD) from $36 to $38, maintaining an Outperform rating due to better-than-expected growth in Daybue sales. The drug's strong performance, driven by STIX growth and potential for European expansion, along with steady Nuplazid sales and upcoming pipeline readouts, suggests significant future sales growth. Despite its current valuation below $4 billion, RBC believes the stock is undervalued given its commercial product potential, noting a low PEG ratio and InvestingPro analysis indicating it as one of the market's most undervalued stocks.
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals announced strong third-quarter 2026 financial results, with total revenues of $342 million, a 22% year-over-year increase. The growth was driven by robust sales of DAYBUE ($140 million, up 39%) and NUPLAZID ($202 million, up 12%). The company also raised its full-year 2026 DAYBUE net sales guidance and provided updates on its clinical pipeline, including upcoming Phase 2 readouts for ACP-211 and remlifanserin in 2027.
Neuren Pharmaceuticals upgrades full year guidance
Neuren Pharmaceuticals has upgraded its full-year 2026 financial guidance for trofinetide income to US$91–93 million, driven by strong third-quarter sales of DAYBUE by partner Acadia Pharmaceuticals. This positive news led to a more than 16% jump in Neuren's shares on the ASX. The company also announced a US$35 million milestone payment from Germany's commercial launch and secured a new US patent extending protection until 2041.
Could Acadia Pharmaceuticals (ACAD) Be 30% Undervalued Following Mixed Q3 Results?
Acadia Pharmaceuticals (ACAD) recently reported mixed Q3 2026 results with revenue of US$342.29 million and net income of US$53.52 million. Despite recent share price weakness, the company is considered 30% undervalued with a fair value of $30.53, supported by disciplined capital allocation and a promising pipeline. Investors are advised to consider both growth prospects and risks before making investment decisions.
Acadia Pharmaceuticals Reports Third Quarter 2026 Financial Results
Acadia Pharmaceuticals announced strong third-quarter 2026 financial results, with total revenues up 22% year-over-year to $342 million, driven by robust sales of DAYBUE and NUPLAZID. The company raised its 2026 DAYBUE net sales guidance and narrowed ranges for NUPLAZID and total revenue. Acadia also provided updates on its pipeline, including Phase 3 development for remlifanserin in Alzheimer’s disease psychosis and anticipated Phase 2 readouts in 2027 for ACP-211 and remlifanserin in Lewy body dementia psychosis.
Acadia Pharma (ACAD) Tops Q3 EPS by 11c, Beats on Revenue; Offers FY26 Revenue Guidance
Acadia Pharma (ACAD) announced Q3 earnings per share of $0.31, exceeding analyst estimates by $0.11, and reported revenue of $342 million, surpassing the consensus of $332.42 million. The company also provided FY2026 revenue guidance, projecting $1.27-1.3 billion, which aligns with analyst expectations.
ACADIA Pharmaceuticals Inc (DR6.DU) Seasonal returns chart - Yahoo Finance
This article from Yahoo Finance presents the seasonal returns chart for ACADIA Pharmaceuticals Inc (DR6.DU), showing the average monthly price return from 2020 to 2026. It includes current stock data and notes an upcoming Q3 2026 earnings call. The page also features various market indices and cryptocurrency prices.
Pomerantz probes Acadia over ADP trial data disclosure
Pomerantz LLP is investigating Acadia Pharmaceuticals Inc. for potential securities fraud after its drug remlifanserin missed the primary endpoint in Phase 2 trials for Alzheimer’s disease psychosis (ADP), causing the stock to drop 12.78%. Despite this, a key secondary endpoint showed statistical significance, and Acadia plans to continue Phase 3 trials, amending them to remove the 30 mg dosage arm. Analysts have lowered price targets but generally maintain positive long-term views on the asset.
Form 4 ACADIA Pharmaceuticals Inc: Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER) For: 15 October
This article reports on a Form 4 filing for ACADIA Pharmaceuticals Inc., specifically detailing an insider transaction involving Mark C. Schneyer, the EVP and Chief Financial Officer, for October 15. The publication date of the article is provided as October 31, 2026, by Investing.com. It is a brief announcement about a regulatory filing without further details on the transaction itself.
Acadia Pharmaceuticals (ACAD) Stock Price, News & Analysis
This article provides an in-depth overview of Acadia Pharmaceuticals (ACAD), a biopharmaceutical company specializing in neurological and rare diseases. It details their commercial products, NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome, highlighting their significance as first and only approved treatments. The report also covers Acadia's pipeline, financial performance, recent news, SEC filings, and upcoming corporate events, offering a comprehensive look for investors.
Form 4 ACADIA Pharmaceuticals Inc: Mark C. Schneyer (EVP, CHIEF FINANCIAL OFFICER) For: 15 October
This article reports on a Form 4 filing for ACADIA Pharmaceuticals Inc, specifically detailing an insider transaction involving Mark C. Schneyer, the Executive Vice President and Chief Financial Officer, for October 15. Form 4 filings are regulatory documents that disclose changes in the ownership of company stock by insiders. The article mentions ACAD's stock performance (-0.82%).
Acadia Pharmaceuticals Inc. (ACAD) Seasonal returns chart
This article provides a seasonal returns chart for Acadia Pharmaceuticals Inc. (ACAD), showing the average monthly price return between 2016 and 2026. It also includes current stock information, such as the real-time price on NasdaqGS and after-hours trading data. The page offers various financial data points like news, statistics, historical data, and analyst profiles for ACAD.
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Acadia Pharmaceuticals Inc. announced its participation in a fireside chat at the UBS Global Biopharma Conference 2026, scheduled for Tuesday, November 17, 2026, at 12:40 p.m. Greenwich Mean Time. A live webcast will be available on the company's website, with an archived recording accessible for approximately one month. Acadia is a biopharmaceutical company focused on developing treatments for neurological and rare diseases.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating potential securities fraud claims against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on behalf of investors. The investigation follows a significant drop in Acadia's stock price after the company announced that its drug remlifanserin "narrowly missed" its primary endpoint in a Phase 2 clinical trial for Alzheimer's disease psychosis. Analysts subsequently downgraded the stock, leading to further declines.
Acadia Pharmaceuticals to Participate in the UBS Global Biopharma Conference 2026
Acadia Pharmaceuticals Inc. announced its participation in a fireside chat at the UBS Global Biopharma Conference 2026 on Tuesday, November 17, 2026, at 12:40 p.m. Greenwich Mean Time. A live webcast will be available on the company's website under the investors section, with an archived recording accessible for approximately one month post-presentation. The company is dedicated to developing innovative treatments for neurological and rare diseases, with a portfolio that includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and a robust pipeline for other underserved patient needs.
Why Acadia Pharmaceuticals Fell Even As Profit Rose
Acadia Pharmaceuticals' stock has fallen 24.9% year-to-date despite European Commission approval for DAYBUE in Rett syndrome and increased Q2 2026 profits. Investors are weighing the success of DAYBUE and NUPLAZID against the failure of remlifanserin in Phase 2 trials for Alzheimer’s psychosis. The current share price of US$19.74 reflects skepticism about the durability of existing brands and the probability of success for remlifanserin's future.
Acadia Pharmaceuticals (ACAD) Stock Dropped, So What Is Driving Attention Now?
Acadia Pharmaceuticals (ACAD) has seen its stock drop significantly, with a 4.6% decrease in the past month and 24.1% over the last three months, trading at US$19.73. Despite this underperformance, the company is considered 35% undervalued with an estimated intrinsic value of $30.53, largely due to its long-term pipeline potential and disciplined capital allocation. Key risks include potential disappointments in remlifanserin Phase 3 data or if existing drugs DAYBUE and NUPLAZID fall short of revenue expectations.
Acadia Pharmaceuticals announces retirement of R&D head, names interim consultant
Acadia Pharmaceuticals announced the retirement of Elizabeth H.Z. Thompson, Ph.D., Executive Vice President and Head of Research and Development, effective Friday. Dr. Thompson will provide limited consulting services through December 31, 2026, as the company seeks a replacement. This leadership transition occurs while Acadia's stock is near its 52-week low, and comes amidst mixed analyst reactions to recent Phase 2 trial results for remlifanserin.
ACADIA Pharmaceuticals Inc. Estimates – NASDAQ:ACAD
This page on TradingView provides financial actuals and estimates for ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with average, high, and low estimates. The platform also allows visualization of financial trends over time for both annual and quarterly data.
Acadia Pharmaceuticals announces retirement of R&D head, names interim consultant
Acadia Pharmaceuticals announced the retirement of Dr. Elizabeth H.Z. Thompson, Executive Vice President and Head of Research and Development, effective Friday. Dr. Thompson will continue to provide limited consulting services until December 31, 2026, while the company seeks a replacement. This transition occurs as Acadia's stock is trading near its 52-week low, and analysts have mixed reactions following recent Phase 2 trial results for remlifanserin.
Press Release: Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Acadia Pharmaceuticals will announce its third quarter 2026 financial results on November 4, 2026, after the market closes. The company will also host a conference call and webcast on the same day to discuss these results and provide a business update. Investors and interested parties can access the call via phone or webcast.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating potential securities fraud claims against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) following a significant drop in its stock price. This decline occurred after the company announced that its Phase 2 clinical trial for remlifanserin "narrowly missed" its primary endpoint, leading to analyst downgrades. The investigation focuses on whether Acadia and its officers engaged in unlawful business practices.
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced that it will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the U.S. financial markets. The company's management team will host a conference call and webcast on the same day at 4:30 p.m. Eastern Time to discuss the results. The webcast will be available on Acadia’s website and an archived version will be available for approximately 90 days.
Acadia Pharmaceuticals to report Q3FY26 results on November 4
Acadia Pharmaceuticals is scheduled to announce its third-quarter 2026 financial results on Wednesday, November 4, 2026, after the close of U.S. financial markets. The company will host a conference call and webcast at 4:30 pm Eastern Time on the same day. This announcement follows a recent investigation by Pomerantz LLP into potential securities fraud after Acadia's stock dropped nearly 20% due to disappointing Phase 2 clinical trial results for remlifanserin in Alzheimer’s disease psychosis.
Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will report its third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of U.S. financial markets. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern Time. Interested parties can register for the call via Acadia's website under the investors section.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
Pomerantz LLP is investigating potential securities fraud claims against ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) on behalf of investors. This investigation follows a significant drop in Acadia's stock price after the company announced that its remlifanserin drug "narrowly missed" its primary endpoint in a Phase 2 clinical trial for Alzheimer’s disease psychosis, leading to analyst downgrades. Investors who suffered losses are encouraged to contact Pomerantz LLP.
Needham keeps USD 35.00 target for ACADIA Pharmaceuticals stock
Needham has reiterated its Buy rating and a USD 35.00 price target for ACADIA Pharmaceuticals. This target is 72.75 percent above the Nasdaq price of USD 20.26 as of October 20, 2026. The company reported a 16.40 percent year-over-year revenue increase in Q2 2026, reaching USD 308.00 million, and is set to report Q3 results on November 4, 2026.
Did Acadia Pharmaceuticals' Fall Catch You Out? What Investors Missed
Acadia Pharmaceuticals experienced a 27.3% fall in share price this year, despite European approval for DAYBUE for Rett syndrome. Investors are weighing the success of DAYBUE against mixed Phase 2 data for remlifanserin and potential legal and regulatory hurdles for its neuropsychiatric pipeline. The current share price of US$19.12 is seen by some narratives as undervalued, highlighting the importance of successful execution in late-stage programs.